{"entity":{"id":"stride-dna-break-detection","kind":"technology","name":"STRIDE DNA break detection (intoDNA)","aka":["STRIDE","SensiTive Recognition of Individual DNA Ends","single-strand break detection","double-strand break detection","DNA damage assay"],"tldr":"STRIDE is a microscope test that lights up individual broken DNA strands inside cells, so a laboratory can count how much DNA damage a tumour carries or a drug causes, cell by cell.","summary":"STRIDE (SensiTive Recognition of Individual DNA Ends) was developed at the Jagiellonian University in Krakow and published in Nucleic Acids Research in 2020 by Magdalena Kordon, Kamil Solarczyk and colleagues. It labels the ends of DNA breaks in fixed cells with a fluorescent signal that is then amplified, so that single-strand breaks (sSTRIDE) and double-strand breaks (dSTRIDE) can be seen and counted directly under a microscope at single-cell resolution, rather than inferred from marker proteins such as gamma-H2AX.\n\nThe first use is in drug development: measuring how much damage chemotherapy, radiotherapy, PARP inhibitors and other DNA damage response drugs cause, and how quickly cells repair it, in cell lines, organoids and patient samples. The longer aim, which intoDNA is pursuing with pharmaceutical partners, is a companion test that reads a tumour's repair capacity to predict who will respond to PARP inhibitors and similar drugs, complementing genomic HRD scores with a functional readout.\n\nSTRIDE is a research tool today; it has no regulatory clearance as a diagnostic, and its clinical value as a predictive test remains to be shown in prospective studies.","status":"emerging","asOf":"2026-09-17","links":[{"label":"intoDNA: STRIDE technology","url":"https://intodna.com"},{"label":"Nucleic Acids Research 2020: STRIDE, a fluorescence method for direct, specific in situ detection of individual single- or double-strand DNA breaks in fixed cells","url":"https://academic.oup.com/nar/article/48/3/e14/5651325"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics","drug-discovery"],"technologies":["hrd-testing","parp-inhibitor"],"targets":[],"drugs":[],"companies":["intodna"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Enzymatically label free DNA ends in fixed cells, amplify the signal with a rolling-circle reaction, and count the fluorescent foci per nucleus to quantify single- and double-strand breaks.","strengths":["Direct detection of breaks rather than a marker protein","Single-cell resolution in tissue and cell culture","Distinguishes single- from double-strand breaks"],"limitations":["Research use only","Needs fixed samples and fluorescence microscopy","Predictive value for treatment not yet shown prospectively"],"since":2020},"route":"/technologies/stride-dna-break-detection/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/"},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"rad51-foci-assay","kind":"technology","name":"RAD51 foci assay (functional HRD test)","route":"/technologies/rad51-foci-assay/"}],"company":[{"id":"intodna","kind":"company","name":"intoDNA","route":"/companies/intodna/"}]}}